The US Supreme Court concluded the Health and Human Services Department misconstrued the law in reducing Medicare payments for drugs purchased by hospitals using the 340B drug discount program, but did not venture into broader questions around court deference to agency interpretation of the law, in a unanimous ruling issued on 15 June.
The decision is a victory for hospitals and a setback for HHS. However, it doesn’t directly impact manufacturers or the...







